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In ﬂuorescence diagnosis with 5-aminolevulinic acid (ALA)-induced porphyrins (FDAP), protoporphyrin IX (PpIX)
accumulation can be macroscopically visualized. Interpretation of these data is still problematic because of the low
reproducibility of the procedure and poor understanding of the mechanisms involved in PpIX tumor selectivity. In
this study, PpIX accumulation is investigated in patients with psoriasis and actinic keratosis (AK) following FDAP.
For this purpose, desquamated lesional and non-lesional skin were incubated with 20% ALA ointment for 3 h, FDAP
was performed, and highly ﬂuorescing lesional skin and non-lesional skin were biopsied. In extracts from these
biopsies, PpIX, protein, and dsDNA were quantiﬁed by spectroﬂuorometry. Digital images acquired with FDAP were
analyzed using image analysis software. PpIX per biopsy in lesional skin in both psoriasis and AK was significantly
higher than in non-lesional skin (po0.05). When corrected for epidermal involvement, only lesional psoriatic
skin showed significantly higher PpIX levels than non-lesional skin. The PpIX-ratio lesional:non-lesional skin
(mean(pmol per mL)  SEM) was 4.12  0.91 in psoriasis and 1.96  0.24 in AK. In FDAP, the ratio of lesional:
non-lesional skin was 1.77  0.06 in psoriasis and 1.37  0.07 in AK. Macroscopic ﬂuorescence and PpIX content
appeared to be well correlated (r¼ 0.73), thus making FDAP a good predictor of PpIX content.
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Photodynamic therapy with 5-aminolevulinic acid (ALA) or
its methylester (MAL) as a topical photosensitizer is gaining
interest in an increasing number of dermatological centers.
In this treatment the preferential accumulation of endog-
enous porphyrines, in particular protoporphyrin IX (PpIX), in
lesional skin after incubation with ALA/MAL is used to treat
various skin diseases (Kennedy et al, 1990; Foley, 2003). As
PpIX has characteristic fluorescence properties, its prefer-
ential accumulation in certain cell types can also be used as
a cellular marker. In fluorescence diagnosis with ALA-in-
duced porphyrins (FDAP), lesional and non-lesional skin is
irradiated with blue (Wood’s) light after incubation of the skin
with ALA. As PpIX shows red fluorescence when excited by
blue light, PpIX accumulating cells can be visualized after
irradiation with Wood’s light (Fritsch et al, 2000). In cases
where demarcation of lesional skin is clinically problematic
or in dermatological screening of field cancerized skin,
FDAP may provide additional information. Interpretation of
these data is still problematic because of the low repro-
ducibility of the procedure due to the numerous factors in-
fluencing fluorescence detection and poor understanding of
the mechanisms involved in PpIX tumor selectivity.
Several different fluorescence detection techniques have
been described by other authors studying PpIX fluores-
cence in human skin and mucosa (Andersson-Engels et al,
1995; Inaguma and Hashimoto, 1999; Wennberg et al, 1999;
Leunig et al, 2001; Ericson et al, 2003b). Because of the
different procedures that have been used, the results are
difficult to compare. Wennberg et al reported a 50% cor-
relation between macroscopic fluorescence imaging and
histological mapping in 22 basal cell carcinoma (BCC)
(Andersson-Engels et al, 1995; Wennberg et al, 1999). Lack
of selectivity and great variation in microscopic intra- and
inter-tumor fluorescence in BCC have been described by
Martin et al (1995), whereas Peng et al (2001) found a highly
selective and homogenous PpIX fluorescence in nodular
BCC after 3 h incubation with MAL. Ericson et al (2003b)
reported that macroscopic fluorescence levels 1.4 times
above the mean normal skin fluorescence were associated
with an abnormal condition in patients with facial BCC after
3–4 h incubation with ALA. The question remains, however,
whether these high fluorescence values are generally as-
sociated with pathologic skin conditions. Macroscopic flu-
orescence intensity after incubation with ALA has been
shown to differ in various skin diseases. Psoriasis has been
reported to have the highest macroscopic fluorescence
values but homogenicity appears to be a problem when
lesions are not pretreated with a keratolytic agent (Fritsch
et al, 2000). Macroscopic fluorescence intensity and intr-
alesional PpIX content after ALA incubation have been
Abbreviations: AK, actinic keratosis; ALA, 5-aminolevulinic acid;
BCC, basal cell carcinoma; FDAP, fluorescence diagnosis with 5-
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studied by Fritsch et al (1999). In this study, macroscopic
fluorescence intensity was assessed by the human eye
and given a value from 0 till 4 according to a fluorescence
standard. With new digital imaging techniques, however,
macroscopic fluorescence can be measured in vivo
more accurately (Ackermann et al, 2000). In the same
study, porphyrins were extracted, assessed by spectro-
fluorometry, and expressed per gram total protein. As PpIX
is thought to be mainly formed in the epidermis, a more
specific epidermal reference to relate PpIX content to would
be more appropriate. As most PpIX is formed in the ep-
idermis and most cellular nuclei are located intraepiderm-
ally, DNA content would be a suitable epidermal marker, The
use of DNA as an epidermal reference has already been
proven useful in several studies (van de Kerkhof et al,
1983a, b).
The aim of this study was to investigate PpIX accumu-
lation in psoriasis and actinic keratosis (AK) and their sur-
rounding clinically normal skin incubated with 20% ALA
ointment for 3 h and to correlate these data to macroscopic
fluorescence using a digital fluorescence imaging system.
When this correlation is known, macroscopic fluorescence
measured on the skin could be used as an estimate for
actual PpIX content in the skin.
Results
Fluorescence spectrometry Fluorescence emission spec-
tra (lexcitation¼408 nm, slit¼ 10 nm) from ALA-treated skin
samples showed maxima at around 630 nm with a smaller
peak at around 700 nm. As PpIX is the predominant ALA-
induced porphyrin metabolite (83.8%–92.6%) (Fritsch et al,
1999) and considering the emission maxima obtained from
the ALA-treated samples to resemble the PpIX reference
standard emission peak, one can assume these emission
maxima at 630 nm to be predominantly caused by PpIX
(Fritsch et al, 1999) (Fig 1). These maxima were most pro-
nounced in ALA-treated skin samples from psoriasis, actinic
keratoses, and their non-lesional skin, respectively. Basal
levels of PpIX were below background fluorescence and
therefore not accurately measurable.
Tissue PpIX content after ALA Lesional skin incubated
with 20% ALA for 3 h showed higher total PpIX content than
non-lesional skin in both psoriasis and AK. Lesional psoria-
tic skin showed higher PpIX levels compared with lesional
skin in AK and non-lesional skin from psoriasis and AK,
respectively (Fig 2, Table I).
Tissue dsDNA content In psoriasis and AK, lesional
dsDNA content was higher compared with non-lesional
skin in both diseases. Lesional psoriatic dsDNA content,
however, was not statistically different from dsDNA content
in lesional AK. When normal surrounding skin in AK and
psoriasis was compared, normal surrounding skin in pso-
riasis appeared to contain more dsDNA than normal sur-
rounding skin in AK (Fig 3, Table I).
Tissue PpIX content after ALA corrected for dsDNA -
When correcting PpIX content for dsDNA content, psoriasis
again showed statistically significantly higher levels of PpIX
compared with normal psoriatic skin. In AK, however, PpIX
levels in lesional skin did not differ from PpIX levels in non-
lesional skin. PpIX content in lesional psoriatic skin was also
higher than in lesional skin in AK (Fig 4, Table I).
Photobleaching studies The PpIX emission peak (630 nm)
declined following irradiation with 415  5 nm at 40 mW per
cm2 (po0.001) (Fig 5). With increasing fluence, a second
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Figure1
Emission spectrum of extracts from 20% 5-aminolevulinic acid
(ALA) (3 h)-incubated psoriatic skin samples and protoporphyrin-IX
(PpIX) reference standard. PS-ALA: psoriatic lesion after 20% ALA (3
h), NS-ALA: normal skin in psoriasis after 20% ALA (3 h). The emission
spectra (lexcitation¼408 nm) of 20% ALA (3 h) incubated psoriatic skin
samples and PpIX reference standard are very similar.
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Figure 2
Tissue protoporphyrin-IX (PpIX) content after 20% 5-amino-
levulinic acid (3 h). From 4 mm punch biopsies, PpIX was extracted
and quantified by spectrofluorometry. po0.05, po0.001. Error
bars denote standard errors of the mean.
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peak arose at 670 nm, which is thought to be the photo-
product of PpIX (Ppp) (Ericson et al, 2003a). The decline in
the PpIX emission peak was most pronounced in pure PpIX
solutions obtained from the PpIX reference standard kit
compared with PpIX-enriched normal skin extracts (Fig 6).
Two-way ANOVA also revealed a significant difference be-
tween the PpIX-enriched and the pure PpIX solutions
(po0.01). This indicates a slower photobleaching of PpIX-
enriched normal skin extracts and is also demonstrated by
a greater fluence required to halve the initial PpIX content
(Fig 6). Considering these half-lives to be relatively high,
possible photobleaching effects due to ambient light expo-
sure during the extraction procedure can therefore be
neglected.
Image analysis In both psoriasis and actinic keratoses,
incubation with 20% ALA for 3 h induced a statistically sig-
nificant increase in lesional skin: normal skin fluorescence
ratio. In psoriasis, this increase was more pronounced than
in AK (Table I, Figs 7 and 8).
Correlation between PpIX content and macroscopic ﬂu-
orescence When all corrected fluorescence data from the
Dyaderm system were compared with their accompanying
PpIX values, a positive correlation was found as seen in
Fig 9. Correlation analysis revealed a correlation coefficient
of r¼ 0.73. When correlation curves for AK and psoriasis
were analyzed separately, the correlation coefficient for AK
appeared to be somewhat higher compared with psoriasis
(r¼0.79 vs 0.69, respectively).
Discussion and Conclusions
Treatment with ALA ointment under an occlusive dressing
for 3 h of lesional and non-lesional skin in AK and psoriasis
induces an increase in biochemical tissue porphyrin con-
tent. This increase was significantly higher in lesional skin
compared with non-lesional skin and was most pronounced
in psoriasis when compared with AK, which is in accord-
ance with other studies (Fritsch et al, 1999). In our study,
porphyrin content was quantified using a PpIX reference
standard. This can be justified as PpIX is the predominant
porphyrin comprising about 75% (Fritsch et al, 1999) of total
ALA-induced porphyrins after 3 h incubation. This also be-
comes clear when the emission spectra obtained from ALA-
treated skin and the PpIX reference standard are compared
(Fig 1). Although the composition of porphyrin metabolites
is known to change in time following ALA application, po-
rphyrin patterns, however, do not significantly differ be-
tween various skin diseases, including normal skin, BCC,
squamous cell carcinoma (SCC), and psoriasis (Fritsch et al,
1999). Furthermore, one can discuss whether these exact
porphyrin compositions are clinically relevant when
Table I. Summary of results
Skin type
PpIX
(pmol per mL)
dsDNA
(lg per mL)
PpIX/dsDNA (pmol
PpIX per lg dsDNA)
PpIX ratio
after ALA
Macroscopic ﬂuorescence ratio
Before ALA After ALA
Psoriasis 27.4  3.1 1.7  0.2 16.3  2.4 4.1  0.9 0.90  0.03 1.77  0.06
Normal skin (psoriasis) 7.80  0.81 1.1  0.2 7.5  1.5
Actinic keratosis 11.8  2.6 1.5  0.3 7.7  1.4 2.0  0.2 0.98  0.03 1.37  0.07
Normal skin (actinic keratosis) 6.2  1.9 0.58  0.09 7.6  1.9
Values are denoted  standard error of the mean.
PpIX, protoporphyrin IX; ALA, 5-aminolevulinic acid.
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Figure 3
Tissue dsDNA content. From 4 mm punch biopsies, dsDNA was
extracted and quantified by spectrofluorometry. po0.05. Error bars
denote standard errors of the mean.
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Figure4
Tissue protoporphyrin-IX (PpIX) content after 20% 5-amino-
levulinic acid (3 h) corrected for dsDNA. PpIX values were divided
by their accompanying dsDNA values. po0.05. Error bars denote
standard errors of the mean.
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performing FDAP as changes in ‘‘porphyrin-like fluores-
cence’’ (630 nm) are measured.
In our study, porphyrins were measured after 3 h ALA
application. This timepoint was found to have optimal
tumor: normal skin contrast ratio when performing FDAP
according to Ericson et al (2003b). For higher lesional flu-
orescence values, a longer incubation period up to 6 h is
needed, but surrounding (normal) skin fluorescence also
increases, thus reducing fluorescence contrast ratio. Tumor:
normal skin ratios of total biochemical tissue porphyrin
content peak between 1 and 4 h of ALA incubation in BCC
and SCC; in psoriasis, however, this ratio is optimal after
6 h ALA incubation (Fritsch et al, 1999).
As PpIX is formed and accumulated mainly in the epi-
dermis, PpIX data were also corrected for epidermal in-
volvement using dsDNA as an epidermal reference. After
this correction, in AK, no statistically significant increase in
PpIX per mg dsDNA was seen any longer after ALA treat-
ment. But, PpIX per mg dsDNA in psoriasis was still signif-
icantly higher after ALA treatment. These findings suggest
different mechanisms being mainly responsible for in-
creased PpIX formation in psoriasis and AK. In psoriasis,
increased PpIX formation per cell may play a more impor-
tant role than in AK. Various mechanisms have been pro-
posed for this by other investigators. Alterations in the
heme-biosynthethic pathway in hyperproliferative tissue are
thought to play an important role in preferential PpIX accu-
mulation including increased porphobilinogen deaminase
(PBGD) and/or decreased ferrochelatase activity (Hinnen
et al, 1998; Krieg et al, 2002). An increased uptake of ALA
by pathologic tissue may also be responsible for increased
PpIX formation, for example due to a defective skin barrier
function, which has been suggested by Martin et al (1995) in
BCC. In psoriasis this may also be the case as defects in
stratum corneum structure have been described (Ghadially
et al, 1996).
Our data show no statistically significant differences in
PpIX content per cell in lesional AK compared with sur-
rounding non-lesional AK. This suggests the number of cells
producing PpIX to be the most important factor for mac-
roscopic skin fluorescence in vivo as seen with FDAP. This is
in parallel with our findings that dsDNA content is signifi-
cantly increased in lesional AK compared with non-lesional
surrounding skin. Although it can not be excluded that in AK
alterations in the heme-biosynthetic pathway or increased
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Figure 5
Emission spectra of irradiated protoporphyrin-IX-enriched normal
skin sample solutions. Excitation wavelength was set to 408 nm.
Samples were exposed to 0, 2.4, 36, 144, and 288 J per cm2 using the
Waldmann Omnilux Blue (415  5 nm, 40 mW per cm2). Note that the
630 nm emission maximum declines and a new maximum arises at 670
nm following higher fluences. Fluorescence intensity was measured in
relative units.
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Figure 6
Photobleaching of protoporphyrin-IX (PpIX)-enriched normal skin
extracts and PpIX solutions. PpIX-enriched normal skin extracts ap-
peared to be less susceptible to photobleaching compared with pure
PpIX solutions (po0.01). Fluorescence intensity was measured in rel-
ative units. NS, normal skin. Error bars denote standard errors of the
mean.
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Figure7
Macroscopic fluorescence in vivo (FDAP) ratio lesional skin: non-
lesional skin in psoriasis and actinic keratosis before and after
incubation with 20% 5-aminolevulinic acid ointment for 3 h.
po0.05, po0.01. Error bars denote standard errors of the mean.
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uptake of ALA may also play a role, this could not be dem-
onstrated in our study. Additional studies analyzing PpIX
accumulation in cell cultured systems of AK and psoriasis
could provide further information concerning this issue.
Initially, total protein was measured as an epidermal ref-
erence value but this did not appear to be an appropriate
reference eventually: protein levels in the biopsies between
lesional and non-lesional skin in psoriasis did not differ
much from each other with a large standard deviation,
which could be explained by the fact that the amount of
dermis in the biopsies was not standardized. As lesional
skin in psoriasis is known to have higher epidermal protein
levels because of the higher proliferation rate, this suggests
the dermis to have a substantial contribution to total protein
content, thus overshadowing differences in epidermal pro-
tein content (van Erp and van de Kerkhof, 1988). DsDNA
quantification revealed evident differences in the four skin
types and appeared to be a good marker for the amount of
epidermal keratinocytes. In hyperproliferative skin condi-
tions, total DNA content is commonly increased due to in-
creased DNA synthesis, which can be a disturbing factor
when a comparison is made with normoproliferative skin. In
a study of Bauer et al (1981), the percentage of cells in the
S-phase in psoriasis appeared to be increased compared
with normal skin (9.7% vs 2.7%). In non-involved psoriatic
skin, this percentage of cells in S-phase was 3.8%. To the
best of our knowledge, in AK, these exact percentages are
not known but when proliferation indices (PI) of psoriasis
and AK were compared (using Ki-67 expression) in a study
of Caldwell et al (1997) AK appeared to have a PI that is 1.26
times the PI in psoriasis. This means that in our samples,
dsDNA values as a marker of the total number of epidermal
keratinocytes could be overestimated. When correcting our
dsDNA data accordingly, lesional psoriatic skin and AK data
had to be decreased by 7.25% and 9.14%, respectively,
and their non-lesional skin to a lesser extent. These cor-
rections, however, did not have a significant effect on our
overall data.
Our results show a positive relation between macro-
scopic fluorescence as measured with our digital imaging
system and biochemical tissue PpIX content. Although
other authors have described in vivo measuring of PpIX,
macro-, and microscopic fluorescence imaging after ALA
treatment or combinations, to the best of knowledge, no
one has linked digital macroscopic imaging directly to bi-
ochemical tissue porphyrin content (Martin et al, 1995;
Figure 8
Normal, fluorescence, and pseudo-color images from psoriatic skin in vivo. Before (A–C) and after incubation with 20% 5-aminolevulinic acid
(ALA) ointment for 3 h (D–F). Incubation with 20% ALA (3 h) ointment induced a remarkable increase in red fluorescence, which was more
pronounced in lesional skin.
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Figure 9
Correlation between protoporphyrin-IX content in the skin and
macroscopic fluorescence at the skin. r¼0.73, po0.001. Dotted
lines indicate 95% confidence intervals.
PpIX AND FLUORESCENCE DIAGNOSIS CORRELATE IN PSORIASIS AND ACTINIC KERATOSIS 837125 : 4 OCTOBER 2005
Wennberg et al, 1999; Ericson et al, 2003b). Especially in the
lower fluorescence range up to 1.0 fluorescence intensity, in
which most actinic keratotic lesions lie, this correlation was
particularly strong (Fig 9). When psoriatic and AK values
were analyzed separately, the slope of the correlation curve
in psoriasis showed a more vertical course (not shown). This
might be explained by the limited penetration into the
deeper skin layers of the blue excitation light in our imaging
system. PpIX deep in the epidermis, which is still detectable
by spectrofluorometric analysis might not be fully excited
and detected by FDAP. This is one of the main limitations of
FDAP and emphasizes the need for adequate desquamat-
ion before performing FDAP. The question remains to what
extent PpIX fluorescence is influenced by a non-standard-
ized desquamation procedure, e.g., curretage, as external
injury to the skin may induce false-positive fluorescence by
a disrupted stratum corneum and/or increased wound re-
pair theoretically. As basal PpIX levels in psoriatic stratum
corneum are increased compared with other skin diseases
(Bissonnette et al, 1998) inadequate desquamation can also
lead to false-positive fluorescence values when performing
FDAP. In our study protocol, desquamation was achieved
by the use of 10% salicylic acid in vaseline twice daily 1 wk
prior to the day of investigation, thus preventing any inter-
ference of scales.
When properly standardized as performed with our dig-
ital imaging system, FDAP appeared to be a good measure
for PpIX content in the skin. This can be helpful in the clin-
ical setting when PpIX accumulation is used for example as
a guiding tool in taking biopsies in field cancerized skin, in
demarcation of (non-melanoma) skin tumors or to evaluate
the treatment efficacy in non-melanoma skin cancer. Fur-
ther studies are, however, needed to scrutinize the mech-
anisms involved in preferential PpIX accumulation and the
factors influencing FDAP, so that fluorescence values can
be adequately interpreted. These data and a standardized
treatment protocol are needed to assess the sensitivity and
specificity of the procedure so that FDAP can become a
more reliable diagnostic tool.
Material and Methods
Study population This study was approved by the local ethics
committee and was conducted according to the Declaration of
Helsinki Principles. After given their written informed consent, 11
patients with plaque-type psoriasis and 11 patients with AK were
included in this study. All patients had a long history of psoriasis or
AK that was histologically confirmed. The studied lesions were all
located on the extremities. Lesional skin was pretreated with 10%
salicylic acid in vaseline for 1 wk prior to the day of ALA application
to remove any scales that could interfere with ALA uptake and/or
light penetration. Prior to ALA application, lesions were photo-
graphed with the DyaDerm digital imaging system (Biocam GmbH,
Regensburg, Germany) after desinfection with 80% denaturated
alcohol vol/vol. Afterward, 20% 5-ALA ointment (Medac Gmbh,
Wedel, Germany) was applied to an area of 5  8 cm including
lesional and non-lesional skin. Over this area, Tegaderm (3 M
Pharmaceuticals, Zoeterwoude, the Netherlands) and aluminum
foil were applied as an occlusive dressing and to protect against
unwanted light effects. Three hours later, the ALA ointment was
removed, again photographs were taken with the digital imaging
system, and 4 mm punch biopsies were taken from non-lesional
skin and fluorescing lesional skin.
Image-capturing procedure The DyaDerm digital imaging system
consists of a flash light (Xenon light source with a custom band-
pass filter (370–440 nm)) and a 12-bit Sony CCD camera combined
in one adjustable arm coupled to a Pentium IV computer equipped
with custom-made image capturing software (Dyaderm Pro v1.4,
Biocam GmbH). The flash light emits 7 light pulses per second to
the skin, which are recorded by the CCD camera (exposure time
100 ms) equipped with a special Schott GG 455 longpass filter to
filter out the excitation light. As PpIX fluorescence emission con-
sists of light in the red spectrum, the red pixels of the CCD camera
(spectral sensitivity at 630 nm between 85% and 90%) were used
to generate a fluorescence image. In this way, a normal colored
image and a fluorescence image were processed in real time. Be-
cause of the short exposition time to the excitation light, photo-
bleaching of PpIX was minimalized in this way. To correct for
different lighting environments between pictures, a fluorescence
reference standard (Maccal 8044, 738-00, Multifoil, Utrecht, the
Netherlands) was included on every image. Images were recorded
in 16-bit grayscale TIFF format.
Skin biopsy procedure The 4 mm punch biopsies were taken in a
darkened room under local anesthesia with 1% xylocain–adrenalin
from highly fluorescing lesional and non-lesional skin after 3 h in-
cubation with 20% ALA ointment. Highly fluorescing areas from
lesional skin were located with the digital imaging system and
marked to identify the site of biopsy. Biopsies from non-lesional
(surrounding) skin were taken out of an area representing mean
non-lesional skin fluorescence. Here again, the site of the biopsy
was carefully selected and marked with the digital imaging system
so that macroscopic fluorescence at the site of biopsy and PpIX
per biopsy matched. Samples were directly frozen into liquid ni-
trogen afterward. To minimize possible PpIX stability problems,
tissue extraction and spectrofluorometrical analysis of PpIX was
performed on the same day.
Tissue extraction procedure The 4 mm punch biopsies were
trimmed to remove a large part of the dermis, frozen in liquid ni-
trogen, and homogenized at 2,000 r.p.m. with the Microdismem-
brator U (B. Braun Biotech International, Melsungen, Germany) for
2 min. Chloroform:methanol (2:1 vol/vol, Merck KgaA, Darmstadt,
Germany) mixture was used as an extraction medium. Mixtures
were centrifuged for 15 min at 15,000 r.p.m. (23,140  g), and the
supernatant was collected for further analysis. A second extraction
cycle was performed by adding the same amount of chloro-
form:methanol (2:1 vol/vol) mixture to the pellet. This mixture was
vortexed for at least 5 min until a new suspension was formed and
centrifuged for 15 min at 15,000 r.p.m. (23,140  g). Subsequently,
the supernantant was collected and added to the supernatant from
the first extraction cycle. The PpIX extraction procedure was iden-
tical to the procedure used by Inaguma and Hashimoto (1999)
apart from our homogenization technique. For dsDNA and protein
extraction out of the remaining pellet, phosphate-buffered saline
(B. Braun, Melsungen, Germany) was used as an extraction me-
dium with a similar extraction protocol as decribed above. All these
steps were performed in a dark laboratory environment taking ul-
timate care to prevent exposure of the specimens to light.
Spectroﬂuorometric analysis In the supernatant, the PpIX con-
tent was assessed by fluorescence spectrophotometry (Shimadzu
RF-5001 PC, Den Bosch, the Netherlands); excitation was set to
408 nm (slit 10 nm) and emission was recorded at 630 nm (slit 10
nm). An emission spectrum (excitation wavelength set at 408 nm)
was also recorded in the range from 450 to 800 nm. For quanti-
fication, a PpIX reference standard was used (Porphyrin Products
Inc., Logan, Utah). Chloroform:methanol (2:1 vol/vol) mixture was
used as a diluent. For protein quantification and dsDNA quantifi-
cation, the Nano Orange protein quantitation kit (Molecular Probes,
Eugene, Oregon) and Picogreen dsDNA quantitation kit (Molecular
Probes) were used, respectively.
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Photobleaching studies and recovery To evaluate possible PpIX
loss due to photobleaching during the extraction protocol and to
assess the internal validity, several photobleaching studies were
performed. In these studies, four different PpIX solutions from the
PpIX calibration curve (84, 33, 12 and 5 pmol per mL PpIX) and four
normal skin extracts with addition of four different PpIX solutions
(104, 54, 26, 13 and 3 pmol per mL PpIX) were exposed to various
fluences (0, 2.4, 36, 144 and 288 J per cm2) using the Waldmann
Omnilux Blue (415  5 nm, 40 mW per cm2, Waldmann Medische
Techniek B.V., Tiel, the Netherlands). These PpIX-enriched normal
skin extracts were produced by mixing 100 mL of PpIX solution with
900 mL of the normal skin extract, resulting in comparable PpIX
concentrations as the four pure PpIX solutions. At each fluence, an
emission spectrum (lexcitation¼ 408 nm, slit¼ 10 nm) was recorded.
The PpIX-enriched concentrations were chosen in the same range
as our measurements of PpIX in ALA-treated skin and were in the
reliable range of our calibration curve. Normal skin was obtained
from excess skin from patients undergoing abdominal plastic
surgery.
Image analysis The 16-bit grayscale TIFF fluorescence images
were imported in NIH ImageJ software (http://rsb.info.nih.gov/ij/).
Because the Xenon light source used for excitation has the highest
intensity in the center of the illuminated area, shading correction
was performed by means of the following algorithm:
S ¼ I=C with C ¼ B=BImax
where B is the blank image (image from a white homogenous
background recorded with the Dyaderm system), BImax the highest
intensity of blank image, I the (uncorrected) image, C the normal-
ized shading image, and S the shading corrected image.
Subsequently, the mean pixel value of the biopsy sites and flu-
orescence standard were measured and recorded. To correct for
different lighting conditions between the pictures, all measured
values were divided by the value of the accompanying fluores-
cence reference standard.
Statistical analysis For analysis of PpIX content, dsDNA values,
and macroscopic fluorescence in vivo a paired two-tailed Stu-
dent’s t-test was used. A p-valueo0.05 was regarded as statis-
tically significant. Correlation analysis of PpIX content and
macroscopic fluorescence in vivo was performed using Pearson’s
correlation analysis. All statistical calculations were performed us-
ing Statistica 6.0 software (Statsoft Inc., http://www.statsoft.com).
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